Cover Image

The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus

Show other versions (1)

Diabetes mellitus (DM) leads to the development of diabetic cardiomyopathy, which is associated with altered nitric oxide (NO)—soluble guanylate cyclase (sGC)—cyclic guanosine monophosphate (cGMP) signalling. Cardioprotective effects of elevated intracellular cGMP-levels have been described in diffe...

Full description

Saved in:
Bibliographic Details
Main Authors: Mátyás, Csaba (Author) , Németh, Balázs Tamás (Author) , Oláh, Attila (Author) , Hidi, László (Author) , Birtalan, Ede (Author) , Kellermayer, Dalma (Author) , Ruppert, Mihály (Author) , Korkmaz-İçöz, Sevil (Author) , Kökény, Gábor (Author) , Horváth, Eszter Mária (Author) , Szabó, Gábor (Author) , Merkely, Béla (Author) , Radovits, Tamás (Author)
Format: Article (Journal)
Language:English
Published: 31 October 2015
In: Cardiovascular diabetology
Year: 2015, Volume: 14, Issue: 1
ISSN:1475-2840
DOI:10.1186/s12933-015-0309-x
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12933-015-0309-x
Get full text
Author Notes:Csaba Mátyás, Balázs Tamás Németh, Attila Oláh, László Hidi, Ede Birtalan, Dalma Kellermayer, Mihály Ruppert, Sevil Korkmaz-Icöz, Gábor Kökény, Eszter Mária Horváth, Gábor Szabó, Béla Merkely and Tamás Radovits
Description
Summary:Diabetes mellitus (DM) leads to the development of diabetic cardiomyopathy, which is associated with altered nitric oxide (NO)—soluble guanylate cyclase (sGC)—cyclic guanosine monophosphate (cGMP) signalling. Cardioprotective effects of elevated intracellular cGMP-levels have been described in different heart diseases. In the current study we aimed at investigating the effects of pharmacological activation of sGC in diabetic cardiomyopathy.
Item Description:Gesehen am 09.06.2020
Physical Description:Online Resource
ISSN:1475-2840
DOI:10.1186/s12933-015-0309-x

Similar Items